Rosen Law Firm Announces Investigation of China Nuokang Bio-Pharmaceutical In Connection With Going Private Proposal from Kin...
October 06 2012 - 11:11AM
Business Wire
The Rosen Law Firm is investigating the Board of Directors of
China Nuokang Bio-Pharmaceutical Inc. (NASDAQ: NKBP) for possible
breaches of fiduciary duty and other violations of corporate law in
connection with a going private proposal from Kingbird Investment
Inc., beneficially owned by Ms. Yuhuan Zhu – the wife of Nuokang's
Chairman and CEO, Mr. Baizhong Xue.
If you would like to join the action please email or call
Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at
pkim@rosenlegal.com or kchan@rosenlegal.com. There is no cost or
obligation to you.
Under the terms of the proposal, offered by Kingbird Investment,
shareholders will receive $5.80 for each American Depository Share
(“ADS”) or $0.725 for each common share of Nuokang they own. The
investigation relates to whether the proposal for $5.80/ADS is fair
to public shareholders and whether Nuokang’s Board fiduciary duties
in connection with the offer.
If you own shares of Nuokang and wish to obtain additional
information, you may contact Phillip Kim or Kevin Chan of The Rosen
Law Firm toll free at 866-767-3653 or via e-mail at
pkim@rosenlegal.com or kchan@rosenlegal.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and
shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar
outcome.
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ:NKBP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about China Nuokang Bio-Pharmaceutical Inc. ADS, Each Representing Eight Ordinary Shares (MM) (NASDAQ): 0 recent articles
More The Rosen Law Firm P.A. News Articles